What is Spyre Therapeutics Inc. Quarterly Revenue?

Spyre Therapeutics Inc. Quarterly Revenue Spyre Therapeutics Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

What is Spyre Therapeutics Inc. Quarterly Net Profit?

Spyre Therapeutics Inc. Quarterly Net Profit Spyre Therapeutics Inc Jun-2026 Quarterly Net Profit is $-36 Million which is growth of 1.4% YoY.

What is Spyre Therapeutics Inc. Annual Revenue?

Spyre Therapeutics Inc. Annual Revenue Spyre Therapeutics Inc Annual Revenue is $0 Million which is growth of 0% YoY.

What is Spyre Therapeutics Inc. Annual Net Profit?

Spyre Therapeutics Inc. Annual Net Profit Spyre Therapeutics Inc Annual Net Profit is $-155 Million which is growth of 25.4% YoY.

What is Spyre Therapeutics Inc. Total Shareholders Fund?

Spyre Therapeutics Inc. Total Shareholders Fund Spyre Therapeutics Inc Dec-2025 Total Shareholders Fund is $559 Million which is growth of 54.5% YoY.

What is Spyre Therapeutics Inc. Total Assets?

Spyre Therapeutics Inc. Total Assets Spyre Therapeutics Inc Dec-2025 Total Assets is $778 Million which is growth of 27.8% YoY.

What is Spyre Therapeutics Inc. Book Value Per Share?

Spyre Therapeutics Inc. Book Value Per Share Spyre Therapeutics Inc Book Value Per Share is $11 which is growth of 118.0% YoY.

What is Spyre Therapeutics Inc. ROE?

Spyre Therapeutics Inc. ROE Spyre Therapeutics Inc ROE is 0% which is growth of 0% YoY.

What is Spyre Therapeutics Inc. Cash From Operating Activity?

Spyre Therapeutics Inc. Cash From Operating Activity Spyre Therapeutics Inc Cash From Operating Activity is $-169 Million which is growth of -7.5% YoY.

What is Spyre Therapeutics Inc. Net Cash Flow?

Spyre Therapeutics Inc. Net Cash Flow Spyre Therapeutics Inc Net Cash Flow is $-4 Million which is growth of 96.3% YoY.

Spyre Therapeutics Inc.

XNAS: SYRE

Download real time

5.79(7.25%)

385.50% Gain from 52W Low

1.1M

XNAS Volume

XNAS 09 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Spyre Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Spyre Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

NEUTRAL
Quarterly Revenue Spyre Therapeutics Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.
POSITIVE
Quarterly Net Profit Spyre Therapeutics Inc Jun-2026 Quarterly Net Profit is $-36 Million which is growth of 1.4% YoY.

Spyre Therapeutics Inc., Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
SR_Q Operating Rev.													0.7
CostOfRevenue_Q Cost Of Rev.	-	-	-	-	-	-	-	-	-	-	-	-	-
GrossProfit_Q Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
OEXPNS_Q Operating Exp. ⌄	81.6	75.6	57.2	56.9	51.9	53.6	61.3	55.4	44.2	47.8	47.8	33.2	29.5
AdminAndSellingExpenses_Q Admin Plus Selling Exp.	16.1	15.2	12.5	11.6	11.8	11.9	10.8	10.7	11.5	12.9	14.1	8.6	12.1
ResearchAndDevlopmentExpenses_Q RnD Exp.	65.5	60.4	44.6	45.3	40.1	41.6	50.5	44.7	32.6	34.9	33.7	24.7	17.4
OP_Q Operating Profit	-81.6	-75.6	-57.2	-56.9	-51.9	-53.6	-61.3	-55.4	-44.2	-47.8	-47.8	-33.2	-28.8
NetNonOperIntIncExp_Q Net Non Operations Interest Incuding Expenses ⌄	10.1	7	7.1	5.4	5.9	6.5	5.8	5.2	5.9	4.4	4.1	1.3	0.4
Others_Q Other Interest Earned	10.1	7	7.1	5.4	5.9	6.5	5.8	5.2	5.9	4.4	4.1	1.3	0.4
IntExpNonOperating_Q Interest Exp. Non Operating	-	-	-	-	-	-	-	-	-	-	-	-	-
PBT_Q Profit Before Tax	-36.2	-69	-62.5	-11.2	-36.7	-44.8	-56.3	-69	-38.8	-43.8	-63.2	-40.1	-217.1
TAX_Q Tax						-0		0		0			0
NICommonStockholders_Q Net Income Common Stockholders ⌄	-36.2	-69	-62.5	-11.2	-36.7	-44.8	2.2	-69	-38.8	-43.9	-63.2	-40.1	-217.1
NP_Q Net Profit	-36.2	-69	-62.5	-11.2	-36.7	-44.8	-56.3	-69	-38.8	-43.9	-63.2	-40.1	-217.1
NIIncludingNoncontrollingInterests_Q Net Income Including Non controlling Interests	-36.2	-69	-62.5	-11.2	-36.7	-44.8	-56.3	-69	-38.8	-43.9	-63.2	-40.1	-217.1
DilutedNIAvailtoComStockholders_Q Diluted NI Avail to Com Stockholders Ann.	-36.2	-69	-62.5	-11.2	-36.7	-44.8	2.2	-69	-38.8	-43.9	-63.2	-40.1	-217.1
EPS_Q Basic EPS	-0.4	-0.7	-0.7	-0.2	-0.6	-0.6	-0.8	-1.4	-0.9	-1.2	-1.8	-	-
AfterDilutedEPS_Q Diluted EPS After ExtraOrdinary	-0.9	-1.1	-0.7	-0.2	-0.8	-0.6	-0.8	-1.4	-0.9	-1.2	-1.8	-	-
SHARE_Q Number Of Shares End	85.1	78.6	74.1	60.8	60.7	60.3	55.3	50.9	45.3	36.5	36.1	-	-
NIContinuingDiscontinuedOper_Q Net Income Continuing Discontinued Operations	-36.2	-69	-62.5	-11.2	-36.7	-44.8	-56.3	-69	-38.8	-43.9	-63.2	-40.1	-217.1
NormalizedIncome_Q Normalized Income	-76.2	-99	-62.5	-11.2	-46.7	-44.8	-56.3	-69	-38.8	-43.9	-65	-32.4	-77
InterestIncome_Q Interest Income	10.1	7	7.1	5.4	5.9	6.5	5.8	5.2	5.9	4.4	4.1	1.3	0.4
INT_Q Interest	-	-	-	-	-	-	-	-	-	-	-	-	-
NetInterestIncome_Q Net Interest Income	10.1	7	7.1	5.4	5.9	6.5	5.8	5.2	5.9	4.4	4.1	1.3	0.4
EBIT_Q EBIT	-81.6	-75.6	-57.2	-56.9	-51.9	-53.6	-61.3	-55.4	-44.2	-47.8	-47.8	-33.2	-28.8
EBITDA_Q EBITDA	-81.6	-75.6	-57.2	-56.9	-51.9	-53.6	-61.3	-55.4	-44.2	-47.8	-47.8	-33.2	-28.2
ReconciledCostOfRevenue_Q Reconciled Cost Of Rev.	-	-	-	-	-	-	-	-	-	-	-	-	-
ReconciledDepreciation_Q Reconciled Depr.	-	-	-	-	-	-					-0.2		0.6
ProfitLossFromContinuingOperations_Q Profit From Continuing Operations	-36.2	-69	-62.5	-11.2	-36.7	-44.8	-56.3	-69	-38.8	-43.9	-63.2	-40.1	-217.1
NormalizedEBITDA_Q Normalized EBITDA	-121.6	-105.6	-57.2	-56.9	-61.9	-53.6	-61.3	-55.4	-44.2	-47.8	-49.6	-22.8	160.5

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Spyre Therapeutics Inc competitor comparison and performance snapshot within industry

Spyre Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEUTRAL
Annual Revenue Spyre Therapeutics Inc Annual Revenue is $0 Million which is growth of 0% YoY.
POSITIVE
Annual Net Profit Spyre Therapeutics Inc Annual Net Profit is $-155 Million which is growth of 25.4% YoY.

Spyre Therapeutics Inc., Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
SR_A Total Rev. Ann. ⌄	-	-				0.9	2.3	18.7			3.9	5.2	4.6	6.1
TotalOperatingRevenues_A Operating Rev. Ann.	-	-				0.9	2.3	18.7			3.9	5.2	4.6	6.1
CostOfRevenue_A Cost Of Rev. Ann.	-	-		-	-	-	-	-	-	-	-	-	-	-
GrossProfit_A Gross Profit Ann.	-	-		-	-	-	-	-	-	-	-	-	-	-
OEXPNS_A Operating Exp. Ann.	36.1%	21.9%	271.3	219.6	208.6	129.5	87.1	84.4	81.5	80.3	49.4	32.9	26.5	17.4
OP_A Operating Profit Ann.	-	-	-271.3	-219.6	-208.6	-128.6	-84.8	-65.7	-81.5	-80.3	-45.5	-27.7	-21.9	-11.3
NetNonOperIntIncExp_A Net Non Operations Interest Incuding Expenses Ann, ⌄	214.6%	110.7%	29.6	24.9	21.3	6.2	0.8	0.1	0.6	2.1	1.2	0.5	0.2	0
Others_A Other Interest Earned Ann.	214.6%	110.7%	29.6	24.9	21.3	6.2	0.8	0.1	0.6	2.1	1.2	0.5	0.2	0
IntExpNonOperating_A Interest Exp. Non Operating Ann.	-	-		-	-	-	-	-	-	-	-	-	-	-
OtherExpenses_A Other Exp. Ann.	-	-		39.5	-20.7	-216.4	-0	-0.1		-0.1	-0.1	-0	-0
PBT_A PBT Ann.	-	-	-178.9	-155.2	-208	-338.8	-84	-65.7	-80.9	-78.3	-44.4	-27.2	-21.7	-11.3
TAX_A Tax Ann.	-	-		-0	0.1	-0	-0.1	0.1	-	-	-	-	-	-
NICommonStockholders_A Net Income Common Stockholders Ann. ⌄	-	-	-178.9	-155.2	-149.6	-338.8	-83.8	-65.8	-80.9	-78.3	-44.4	-27.2	-21.7	-11.5
NP_A Net Profit Ann.	-	-	-178.9	-155.2	-208	-338.8	-83.8	-65.8	-80.9	-78.3	-44.4	-27.2	-21.7	-11.3
NIIncludingNoncontrollingInterests_A Net Income Including Non controlling Interests Ann.	-	-	-178.9	-155.2	-208	-338.8	-83.8	-65.8	-80.9	-78.3	-44.4	-27.2	-21.7	-11.3
DilutedNIAvailtoComStockholders_A Diluted NI Avail to Com Stockholders Ann.	-	-	-178.9	-155.2	-149.6	-338.8	-83.8	-65.8	-80.9	-78.3	-44.4	-27.2	-21.7	-11.5
EPS_A EPS Ann.	-	-		-2	-3.2	-49.1	-	-	-	-	-	-	-	-
DilutedEPS_A Diluted EPS Ann.	-	-		-2	-3.2	-49.1	-	-	-	-	-	-	-	-
SHARE_Q Number Of Shares End	-	-		74.1	55.3	36.1	-	-	-	-	-	-	-	-
TotalExpenses_A Total Exp. Ann.	36.1%	21.9%		219.6	208.6	129.5	87.1	84.4	81.5	80.3	49.4	32.9	26.5	17.4
NIContinuingDiscontinuedOper_A Net Income Continuing Discontinued Operations Ann.	-	-	-178.9	-155.2	-208	-338.8	-83.8	-65.8	-80.9	-78.3	-44.4	-27.2	-21.7	-11.3
NormalizedIncome_A Normalized Income Ann.	-	-	-248.9	-165.2	-208	-141.5	-83.8	-65.8	-80.9	-78.3	-44.4	-27.2	-21.7	-11.3
InterestIncome_A Interest Income Ann.	214.6%	110.7%	29.6	24.9	21.3	6.2	0.8	0.1	0.6	2.1	1.2	0.5	0.2	0
INT_A Interest Ann.	-	-		-	-	-	-	-	-	-	-	-	-	-
EBITDA_A EBITDA Ann.	-	-	-271.3	-219.6	-208.6	-127.8	-83.2	-64.1	-80.5	-79.9	-45.2	-27.4	-21.8	-11.2
ReconciledCostOfRevenue_A Reconciled Cost Of Rev. Ann.	-	-		-	-	-	-	-	-	-	-	-	-	-
ReconciledDepreciation_A Reconciled Depr. Ann.	-	-				0.7	1.6	1.6	1	0.4	0.3	0.3	0.1	0.1
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	-	-178.9	-155.2	-208	-338.8	-83.8	-65.8	-80.9	-78.3	-44.4	-27.2	-21.7	-11.3
NormalizedEBITDA_A Normalized EBITDA Ann.	-	-	-341.3	-229.6	-208.6	69.5	-83.2	-64.1	-80.5	-79.9	-45.2	-27.4	-21.8	-11.2

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Operating Exp. Ann.

1Y CHG

5.3%

2Y CAGR

30.2%

3Y CAGR

36.1%

5Y CAGR

21.9%

7Y CAGR

23.8%

10Y CAGR

28.9%

Operating Expenses Annual Cr growth is lower than historical averages.

Spyre Therapeutics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Total Shareholders Fund Spyre Therapeutics Inc Dec-2025 Total Shareholders Fund is $559 Million which is growth of 54.5% YoY.
POSITIVE
Total Assets Spyre Therapeutics Inc Dec-2025 Total Assets is $778 Million which is growth of 27.8% YoY.

Spyre Therapeutics Inc., Balance Sheet, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
TA_A Total Assets Ann. ⌄	122%	36.9%	777.8	608.5	341.9	71.1	109.9	161.6	83.2	77.7	56.1	67.1	38.7
CA_A Total Current Assets Ann.	132%	39%	777.8	608.5	341.5	62.3	98.9	149.8	74.5	76.7	55	66.4	38.3
CashEquivalentsShortTermInvestments_A Cash Equivalents and Short Term Investments Ann.	138.6%	38.9%	756.5	603.1	339.3	55.7	93.1	146.3	72	74.5	50.3	63.5	33.1
Receivables_A Change In Account Receivables Ann.	-	-	-	-		0.4	0.8	-	-		3.1	1.2	1.7
Inventories_A Inventories Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
OtherCurrentAssets_A Other Current Assets Ann.	50.9%	-	21.3	5.4	2.3	6.2	-	-	-	-	-	-	-
TotalNonCurrentAssets_A Total Non Current Assets Ann.	-	-		0	0.3	8.9	11	11.8	8.7	1.1	1.1	0.6	0.4
NetPPE_A Net PPE Ann.	-	-	-	-		6.7	8.4	9.9	7.1	1	0.9	0.6	0.4
InvestmentsAndAdvances_A Investments & Advances Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
OtherNonCurrentAssets_A Other Non Current Assets Ann.	-	-	-	0	0.3	2.2	2.7	2	1.6	0.1	0.2	0	0
TotalLiabilitiesNetMinorityInterest_A Total Liabilities Net Minority Interest Ann. ⌄	44.4%	23.5%	62.6	90.7	157.8	20.8	26	21.8	23.1	10.3	5.7	4.1	2.6
CL_A Total Current Liabilities Ann.	58.7%	29.1%	58.7	54.1	32	14.7	20.1	16.4	18.4	10.2	5.6	4	2.5
PayablesAndAccruedExpenses_A Payables & Accrued Exp.s Ann.	46.2%	18.3%	27.8	22.8	26.1	8.9	11.6	12	14.3	7.5	3.6	2.4	1.9
CurrentDebtCapLeaseObligation_A Current Debt Cap Lease Obligation Ann.	-	-	-	-	-	0.6	0.4	0.3	0.4	-	-	-	-
CurrentDeferredLiabilities_Q Current Deferred Liabilities	-	-	-	-		0.5	2.4	-	-		0	0.1	-
OtherCurrentLiabilities_A Other Current Liabilities Ann.	-	115.1%	23	25.6	1.9	-	0.8	0.5	0.5	0.1	0.2	0.2	0.1
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann.	-14.3%	-6%	3.9	36.6	125.9	6.2	5.8	5.3	4.7	0.1	0.1	0.1	0
LongTermDebtAndCapitalLeaseObligation_Q LT Debt & Capital Lease Obligation	-	-	-	-		4	4.6	5.1	4.7	-	-	-	-
TradeandOtherPayablesNonCurrent_A Trade & Other Payables Non Current Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalDeferredCreditsAndOtherNonCurrentLiabilities_A Total Deferred Credits & Other Non Current Liabilities Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	123.2%	32%	559.4	362	-0.9	50.3	83.9	139.8	60.1	67.4	50.3	63	36.1
EQCAP_A Equity Share Capital Ann.	142.3%	38.6%	715.2	517.8	184	50.3	83.9	139.8	60.1	67.4	50.3	63	36.1
CapitalStock_A Capital Stock Ann.	-	-	155.8	155.8	184.9	0	0	0
RetainedEarnings_A Retained Earnings Ann.	-	-	-1,127.6	-972.4	-764.4	-425.6	-341.8	-276	-195.1	-116.9	-72.5	-45.3	-23.6
GainsLossesNotAffectingRetainedEarnings_A Gains Losses Not Affecting Retained Earnings Ann.	-	-	0.9	0.2	0.3	-0.1	-0	0	0.1	-0	-0.1
TotalCapitalization_A Total Capitalization Ann.	142.3%	38.6%	715.2	517.8	184	50.3	83.9	139.8	60.1	67.4	50.3	63	36.1
TangibleAssets_A Tangible Assets Ann.	142.3%	38.6%	715.2	517.8	184	50.3	83.9	139.8	60.1	67.4	50.3	63	36.1
WC_A Working Capital Ann.	147.2%	40.1%	719.1	554.4	309.6	47.6	78.8	133.4	56.2	66.4	49.4	62.5	35.8
InvestedCapital_A Invested Capital Ann.	123.2%	32%	559.4	362	-0.9	50.3	83.9	139.8	60.1	67.4	50.3	63	36.1
TangibleBookValue_A Tangible Book Value Ann.	123.2%	32%	559.4	362	-0.9	50.3	83.9	139.8	60.1	67.4	50.3	63	36.1
Borrowings_A Borrowings Ann.	-	-	-	-		4.6	5.1	5.5	5.1	-	-	-	-
NetDebt_A Net Debt Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
ShareIssued_A Share Issued Ann.	211%	110.3%	78.2	60.3	36.1	2.6	2	1.9	1.2	1	0.7	0.5	0.5
SHARE_Q Number Of Shares End	-	-	74.1	55.3	36.1	-	-	-	-	-	-	-	-

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Assets Ann.

1Y CHG

27.8%

2Y CAGR

50.8%

3Y CAGR

122%

5Y CAGR

36.9%

7Y CAGR

39%

10Y CAGR

35%

Total Assets Annual growth is lower than historical averages.

Total Current Liabilities Ann.

1Y CHG

8.5%

2Y CAGR

35.4%

3Y CAGR

58.7%

5Y CAGR

29.1%

7Y CAGR

28.4%

10Y CAGR

37.1%

Total Current Liabilities Annual Cr growth is lower than historical averages.

Total ShareHolders Funds Ann.

1Y CHG

54.5%

3Y CAGR

123.2%

5Y CAGR

32%

7Y CAGR

35.3%

10Y CAGR

31.5%

Total ShareHolders Funds Annual growth is stable compared to historical averages.

Spyre Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Book Value Per Share Spyre Therapeutics Inc Book Value Per Share is $11 which is growth of 118.0% YoY.
NEUTRAL
ROE Spyre Therapeutics Inc ROE is 0% which is growth of 0% YoY.

Spyre Therapeutics Inc., Ratios, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
ROA_A RoA Ann. %	-	-	-	-31.47%	-164.06%	-92.58%	-48.46%	-66.09%	-97.26%	-66.28%	-44.24%	-41.05%	-55.42%
ROE_A ROE Ann. %	-	-	-	-82.84%	-1,371.79%	-124.87%	-58.81%	-80.93%	-122.74%	-75.32%	-48.08%	-43.80%	-93.56%
ROIC_Q ROIC %	-	-	-	-0.9	-	-30.1	-20.9	-15.9	-29.2	-23.4	-12.5	-8.5	-45.8
OPMPCT_A OPM Ann. %	-	-	-	-	-14,510.61%	-3,640.23%	-350.33%	-	-	-1,169.32%	-531.72%	-473.34%	-185.95%
NBTO_A Inventory Turnover Ratio Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
ASETTO_A Asset Turnover Ann. %	-	-	-	-		0	0.1	-	-	0.1	0.1	0.1	0.3
WCTO_A Working Capital Turnover Ann.	-	-				0.1	0.2			0.1	0.1	0.1	0.2
QuickRatio_A Quick Ratio Ann.	-	-	-	11.2	10.6	3.8	4.7	8.9	3.9	7.3	9.5	16.3	13.8
CRATIO_A Current Ratio Ann.	-	-	-	11.3	10.7	4.3	4.9	9.1	4.1	7.5	9.8	16.8	15.2
IC_A Interest Coverage Ratio Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
LTDE_A LT Debt To Equity Ann.	-	-	-	-	-	0.1	0.1	0	0.1	-	-	-	-

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Spyre Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Cash From Operating Activity Spyre Therapeutics Inc Cash From Operating Activity is $-169 Million which is growth of -7.5% YoY.
POSITIVE
Net Cash Flow Spyre Therapeutics Inc Net Cash Flow is $-4 Million which is growth of 96.3% YoY.

Spyre Therapeutics Inc., Cash Flow, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
CFO_A Cash from Operating Act. Ann. ⌄	-	-	-169.3	-157.4	-99.9	-80.1	-53.7	-75.8	-65.7	-32.2	-24.6	-18.8	-11
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	-	-155.2	-208	-338.8	-83.8	-65.8	-80.9	-78.3	-44.4	-27.2	-21.7	-11.3
DepreciationAmortizationDepletion_A Depreciation Amortization Depletion Ann.	-	-			0.7	1.6	1.6	1	0.4	0.3	0.3	0.1	0.1
DepreciationAndAmortization_A Depreciation And Amortization Ann.	-	-			0.7	1.6	1.6	1	0.4	0.3	0.3	0.1	0.1
DeferredTax_A Deferred Tax Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
DeferredIncomeTax_A Deferred Income Tax Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
EmployeesStockOptions_A ESOPs Ann.	74.3%	42.9%	37.6	44.8	25.7	7.1	8	6.3	4.9	4.3	2.5	1.2	0.8
OtherNonCashItems_A Other Non Cash Items Ann.	-	-	-29.8	20.4	19.2	0.4	0.4	0.6	0.5	0.1	-0	0.1	0.8
ChangeInWorkingCapital_A Change In Working Capital Ann.	-	-	-5.9	-4.5	-5.2	-5.5	1.8	-2.5	7.1	7.2	-0.2	1.5	-1.3
ChangeInReceivables_A Change In Receivables Ann.	-	-			0.4	0.4	-0.8	-		3.1	-1.9	0.5	-1.7
ChangeInInventory_A Change In Inventory Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
ChangePayablesAccruedExpense_A Change Payables Accrued Expense Ann.	-	-	6.9	-1.6	-7.1	-3.5	0.7	-1.7	7.7	4.4	1.8	1.8	1
ChangeInOtherCurrentAssets_A Change In Other Current Assets Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
ChangeInOtherCurrentLiabilities_A Change In Other Current Liabilities Ann.	-	-			-2.3	-0.4	-0.4	0.3	-0.3	-	-	-	-
ChangeInOtherWorkingCapital_A Change In Other Working Capital Ann.	-	-	-	-	0.6	-0.9	3.6	-	-	-0	-0.1	0.1	-
CFI_A Cash from Investing Act. Ann. ⌄	-	-	-143.5	-353.3	-108.4	57	-22.6	-7.6	-1.7	-15.2	-22.5	-12.1	-4
NetPPEPurchaseAndSale_A Net PPE Purchase & Sale Ann.	-	-			0.5	-0	-0.6	-4.3	-1.5	-0.4	-0.6	-0.2	-0.2
PurchaseOfPPE_A Purchase Of PPE Ann.	-	-	-			-0	-0.6	-4.3	-1.5	-0.4	-0.6	-0.2	-0.2
NetBusinessPurchaseAndSale_A Net Business Purchase & Sale Ann.	-	-			3	-	-	-	-	-	-	-	-
PurchaseOfBusiness_A Purchase Of Business Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
PurchaseOfInvestment_A Purchase Of Investment Ann.	-	-	-522.2	-599.3	-166.8	-39.5	-133.1	-129	-91.9	-62.2	-64.1	-20.4	-3.8
SaleOfInvestment_A Sale Of Investment Ann.	56.7%	24.2%	371.7	246	39.9	96.6	111	125.7	91.7	47.4	42.2	8.5	-
NetOtherInvestingChanges_A Net Other Investing Changes Ann.	-	-	-	-	-	-	-	-	-	-	-	0.1	-0
CFA_A Cash from Financing Act. Ann. ⌄	93.4%	14.9%	309	410.9	361.1	42.7	1.4	154.5	65.7	57.1	12.2	49.4	41.7
NetIssuancePaymentsOfDebt_A Net Issuance Payments Of Debt Ann.	-	-	-		-0	-0.4	-0.5	-0	-0	-	-	-	-
NetLongTermDebtIssuance_A Net Long Term Debt Issuance Ann.	-	-	-		-0	-0.4	-0.5	-0	-0	-	-	-	-
NetShortTermDebtIssuance_A Net ST Debt Issuance Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
NetCommonStockIssuance_A Net Common Stock Issuance Ann.	93.6%	15.1%	311.1	236.4	169.1	42.9		153.7	64.3	54.1	11.4	49.3	43.7
CommonStockIssuance_A Common Stock Issuance Ann.	93.6%	15.1%	311.1	236.4	169.1	42.9		153.7	64.3	54.1	11.4	49.3	43.7
CommonStockPayments_A Common Stock Payments Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
dividend_1Y_actual Dividend 1year	-	-
DividendPerShare_A Dividend Per Share Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
NetOtherFinancingCharges_A Net Other Financing Charges Ann.	-	-	-5.4	-1.8	-5.8	-	-	-	-	-	-	-	-2
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	33%	-1.4%	85.7	89.4	189.2	36.4	17	91.9	20.8	22.5	12.8	47.8	29.3
NetIncDecInCashAndCashEquivalents_A Net Increase In Cash Plus Cash Eqv.s Ann.	-	-	-3.7	-99.8	152.8	19.5	-74.9	71.1	-1.7	9.6	-34.9	18.5	26.7
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	73.9%	33.9%	89.4	189.2	36.4	17	91.9	20.8	22.5	12.8	47.8	29.3	2.6
IncomeTaxPaidSupplementalData_A Income Tax Paid Supplemental Data Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
InterestPaidSupplementalData_A Interest Paid Supplemental Data Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
CapitalExpenditure_A Capex Ann.	-	-	-	-	-	-0	-0.6	-4.3	-1.5	-0.4	-0.6	-0.2	-0.2
IssuanceOfCapitalStock_A Issuance Of Capital Stock Ann.	93.6%	15.1%	311.1	405.2	366.5	42.9		153.7	64.3	54.1	11.4	49.3	43.7
IssuanceOfDebt_A Issuance Of Debt Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
RepaymentOfDebt_A Repayment Of Debt Ann.	-	-	-		-0	-0.4	-0.5	-0	-0	-	-	-	-
RepurchaseOfCapitalStock_A Repurchase Of Capital Stock Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
FreeCashFlow_A Free Cash Flow Ann.	-	-	-169.3	-157.4	-99.9	-80.2	-54.3	-80.1	-67.2	-32.6	-25.2	-19.1	-11.2

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Cash from Financing Act. Ann.

1Y CHG

-24.8%

2Y CAGR

-7.5%

3Y CAGR

93.4%

5Y CAGR

14.9%

7Y CAGR

27.3%

10Y CAGR

22.2%

Cash from Financing Annual Activity is falling faster than historical averages.

Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow

385.50% Gain from 52W Low

Spyre Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

Spyre Therapeutics Inc - Earnings Report - Quarterly Results

Spyre Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Quarterly Revenue Spyre Therapeutics Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

Quarterly Net Profit Spyre Therapeutics Inc Jun-2026 Quarterly Net Profit is $-36 Million which is growth of 1.4% YoY.

Spyre Therapeutics Inc - Competitors/Peers

Spyre Therapeutics Inc competitor comparison and performance snapshot within industry

Spyre Therapeutics Inc - Earnings Report - Annual Results

Spyre Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Annual Revenue Spyre Therapeutics Inc Annual Revenue is $0 Million which is growth of 0% YoY.

Annual Net Profit Spyre Therapeutics Inc Annual Net Profit is $-155 Million which is growth of 25.4% YoY.

Spyre Therapeutics Inc - Balance Sheet

Spyre Therapeutics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Total Shareholders Fund Spyre Therapeutics Inc Dec-2025 Total Shareholders Fund is $559 Million which is growth of 54.5% YoY.

Total Assets Spyre Therapeutics Inc Dec-2025 Total Assets is $778 Million which is growth of 27.8% YoY.

Spyre Therapeutics Inc - Ratios

Spyre Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Book Value Per Share Spyre Therapeutics Inc Book Value Per Share is $11 which is growth of 118.0% YoY.

ROE Spyre Therapeutics Inc ROE is 0% which is growth of 0% YoY.

Spyre Therapeutics Inc - Cash Flow

Spyre Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Cash From Operating Activity Spyre Therapeutics Inc Cash From Operating Activity is $-169 Million which is growth of -7.5% YoY.

Net Cash Flow Spyre Therapeutics Inc Net Cash Flow is $-4 Million which is growth of 96.3% YoY.